Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24179476 | 0.78 | CYP11B2 (0.33) | ALDH1A1NPSR1TDP1 | |
| SCHEMBL23380207 | 0.77 | ALDH1A1 (0.33) | ALDH1A1NPSR1TDP1 | |
| SCHEMBL7897998 | 0.75 | CSNK1A1 (0.37) | XDHSYKALDH1A1NPSR1 | |
| SCHEMBL4064950 | 0.75 | ALDH1A1 (0.53) | ALDH1A1NPSR1TDP1 | |
| SCHEMBL26167991 | 0.75 | HTT (0.41) | XDHALDH1A1 | |
| SCHEMBL20389682 | 0.75 | CYP11B1 (0.37) | XDHALDH1A1NPSR1 | |
| SCHEMBL459834 | 0.75 | CHEK1 (0.37) | TTRALBXDH | |
| SCHEMBL25377425 | 0.72 | ENPP2 (0.36) | XDH | |
| SCHEMBL4766176 | 0.71 | CYP11B1 (0.42) | ALDH1A1 | |
| SCHEMBL30973945 | 0.71 | XDH (0.54) | XDHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111655700-B | Oxadiazolopyridine derivatives as ghrelin O-acyltransferase (GOAT) inhibitors | 勃林格殷格翰国际有限公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-3746451-B1 | BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-07-12 | — | — | EP | disclosed |
| US-11254688-B2 | Benzyl-, (pyridin-3-yl)methyl -or (pyridin-4-yl)-methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-22 | — | — | US | disclosed |
| US-20210053985-A1 | BENZYL-, (PYRIDIN-3-YL)METHYL -OR (PYRIDIN-4-YL)-METHYL-SUBSTIITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-25 | — | — | US | disclosed |
| EP-3746451-A1 | BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2020-12-09 | — | — | EP | disclosed |
| CN-111655700-A | Benzyl-, (pyridin-3-yl) methyl-or (pyridin-4-yl) methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyltransferase (GOAT) inhibitors | 勃林格殷格翰国际有限公司 | 2020-09-11 | — | — | CN | disclosed |
| WO-2019149657-A1 | BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-08 | — | — | WO | disclosed |
| EP-2668184-B1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | PF MEDICAMENT (FR) | 2018-01-10 | — | — | EP | disclosed |
| EP-2877176-B1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING TRK | PF MEDICAMENT (FR) | 2017-04-26 | — | — | EP | disclosed |
| EP-2877177-B1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN | PF MEDICAMENT (FR) | 2016-10-26 | — | — | EP | disclosed |
| EP-2877176-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING TRK | Pierre Fabre Médicament (FR) | 2015-06-03 | — | — | EP | disclosed |
| US-8883821-B2 | Substituted pyrazolo[3,4-b]pyridines as medicaments | PIERRE FABRE MEDICAMENT (FR) | 2014-11-11 | — | — | US | disclosed |
| WO-2014016434-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING TRK | PIERRE FABRE MEDICAMENT (FR) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014016433-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN | PIERRE FABRE MEDICAMENT (FR) | 2014-01-30 | — | — | WO | disclosed |
| EP-2689778-A1 | Derivatives of azaindoles or diazaindoles for treating pain | PIERRE FABRE MEDICAMENT (FR) | 2014-01-29 | — | — | EP | disclosed |
| EP-2689779-A1 | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk | PIERRE FABRE MEDICAMENT (FR) | 2014-01-29 | — | — | EP | disclosed |
| EP-2668184-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | Pierre Fabre Medicament (FR) | 2013-12-04 | — | — | EP | disclosed |
| US-20130172360-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | disclosed |
| US-20130085144-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | PIERRE FABRE MEDICAMENT (FR) | 2013-04-04 | — | — | US | disclosed |
| WO-2012101239-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | PIERRE FABRE MEDICAMENT (FR) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085144-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | MAP2K5, MAP2K2, MAP2K3 | TTR 1265/4885ALB 1573/4885XDH 968/4885 |
| US-20130172360-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | MAP2K5, MAP2K2, MAP2K3 | TTR 1265/4885ALB 1573/4885XDH 968/4885 |
| US-20210053985-A1 | BENZYL-, (PYRIDIN-3-YL)METHYL -OR (PYRIDIN-4-YL)-METHYL-SUBSTIITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | MBOAT4, GIPR, ADIPOR1 | TTR 1205/4885ALB 2755/4885XDH 2090/4885 |
| US-11254688-B2 | Benzyl-, (pyridin-3-yl)methyl -or (pyridin-4-yl)-methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors | MBOAT4, ADIPOR1, GIPR | TTR 1266/4885ALB 2309/4885XDH 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.